Page last updated at 15:35 GMT, Thursday, 17 January 2008

Breast cancer drug 'breakthrough'

Tamoxifen tablets
Some patients find the anti-cancer drug simply stops working

Scientists believe they have made a breakthrough in a treatment for breast cancer.

Some women using the anti-cancer drug tamoxifen have found it stopped working.

Now researchers at Tenovus Centre for Cancer Research at Cardiff University say they have found a way to halt or even reverse resistance to the drug.

The research centre said the discovery could provide a huge boost to patients fighting the disease.

Scientist have discovered that by inhibiting the activity of a certain chemical in cancer cells, tamoxifen continues to work.

The chemical is a protein known as Src, and researchers have found it is more active in laboratory grown breast cancer cells.

The ability to restore sensitivity to therapy, or to even prevent resistance arising in the first place, could be of huge benefit
Prof Robert Nicholson, Tenovus Research Centre

But as part of research with the medical giant AstraZeneca, the Tenovus centre found it could treat cancer cells with a new drug which halted the Src protein.

The drug, which is now in very early clinical trials, is known for now by its lab name of AZD0530.

Used along with tamoxifen, scientists say that in laboratory trials it appears to prevent and even reverse resistance to the anti-cancer drug.

Huge benefit

Prof Robert Nicholson, director of the Tenovus Centre for Cancer Research, said it was an important milestone in their research.

"Whilst little is known about the mechanisms used by breast cancers to become resistant to common therapies such as Tamoxifen, it remains a significant clinical problem," he explained.

"Therefore the ability to restore sensitivity to therapy, or to even prevent resistance arising in the first place, could be of huge benefit to a large number of breast cancer patients."

Tamoxifen is one of the main drugs used to tackle hormone-sensitive breast cancer, and is usually taken by patients for five years to prevent the disease returning.

It can also be used to treat women at high risk, with studies estimating that the drug can cut the risk of developing hormone-sensitive breast cancer by more than a third.



Print Sponsor


SEE ALSO
Drug 'cuts long-term cancer risk'
21 Feb 07 |  Health
Breast cancer drug 'cuts deaths'
13 Feb 07 |  Health
Breast cancer
10 Jul 09 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC iD

Sign in

BBC navigation

Copyright © 2018 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific